

## Assignment

WHEREAS, I/we, **Dramane I. LAINE** of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, a citizen of France; **Michael R. PALOVICH** of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States of America, a citizen of the United States of America; **Alexander G. PRESTON** of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY, United Kingdom, a citizen of the United Kingdom; and **Anthony William James COOPER** of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY, United Kingdom, a citizen of the United Kingdom, respectively, has/have invented or discovered certain improvements in **MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS**, hereinafter referred to as said invention, and improvements for which a priority application **60/536092** was filed on **13 January 2004** in the United States Patent and Trademark Office and for which a PCT international application is now being filed designating the United States of America and naming assignor as inventor, and in the United States only applicant/inventor. I/We hereby authorize and request that the filing date and application number of said PCT application, when known be inserted in parentheses below.

(PCT/US2005/001333 filed 13 January 2005)

WHEREAS, **GLAXO GROUP LIMITED**, a company incorporated in England, whose registered office is at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, **Dramane I. LAINE**, **Michael R. PALOVICH**, **Alexander G. PRESTON**, and **Anthony William James COOPER**, for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said **GLAXO GROUP LIMITED**, throughout the United States of America, its territories and possessions, and in and to said application and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America;

AND, my/our whole right, title and interest in and to said invention and improvements to **GLAXO GROUP LIMITED**, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

AND, I/we do hereby authorize and request the issue of any Letters Patent in the respective areas referred to, to said **GLAXO GROUP LIMITED**, as assignees of my/our whole right, title and interest in and to the same for the sole use and behalf of the said assignees, their successors and assigns as their interests appear herein;

AND, I/we warrant that I/we have not knowingly conveyed to others any right in said invention, improvements, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing said invention and improvements and that I/we have good right to assign the same to **GLAXO GROUP LIMITED**;

AND, I/we the undersigned, **Dramane I. LAINE, Michael R. PALOVICH, Alexander G. PRESTON**, and **Anthony William James COOPER**, for the consideration aforesaid, do hereby agree that I/we or my/our executors or legal representatives, will provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, application papers, affidavits, assignments and other documents which may be necessary or desirable to more effectually secure to and vest in said **GLAXO GROUP LIMITED**, their successors and assigns, the whole right, title and interest in and to the said invention and improvements, applications, Letters Patent, rights, title and interest hereby sold, assigned and conveyed, or intended so to be. *This assignment should be deemed effective as of 13 January 2004.*


IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

Inventor: **DRAMANE I. LAINE**


Date

*28 Mar 2006*

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

  
 Inventor: **Michael R. PALOVICH** 3/29/06  
Date

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

  
 Inventor: **Alexander G. PRESTON** 09-MAR-2006  
Date

IN WITNESS WHEREOF, I/we have hereunto set my/our hand(s) and affixed my/our seal(s) on the date(s) indicated below.

  
 Inventor: **Anthony William James COOPER** 9 Mar 06  
Date

## U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	PCT/US2005/001333
	<b>Filing Date</b>	13 January 2005
	<b>First Named Inventor</b>	Dramane Ibrahim LAINE
	<b>Title</b>	Muscarinic Acetylcholine Receptor Antagonists
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	PU60660

I hereby appoint:

☒ Practitioners associated with the Customer Numbers.      20462  
Or  
☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:


☐ The address associated with the above-mentioned Customer Number:  
Or  
☒ The address associated with Customer Number 20462  
Or  
☐ Firm or Individual Name:

Address:		
Address:		
City:	State:	Zip:
Country:		
Telephone:	Fax:	

I am the:

☐ Applicant/Inventor:  
☒ Assignee or record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature: 	Date: 10 July 2006
Name: <b>Stephen Venetianer</b>	Telephone: 610-270-5040
Title and Company: <b>Vice President, Pharmaceuticals, Glaxo Group Limited</b>	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of:      forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner: GLAXO GROUP LIMITED****Application No./Patent No.: PCT/US2005/001333 Filed/Issue Date: 13 January 2005****Entitled: Muscarinic Acetylcholine Receptor Antagonists****GLAXO GROUP LIMITED, a company incorporated in England and Wales, states that it is:**

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_% in the patent application/patent identified above by virtue of either;

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.


3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
\_\_\_\_\_  
Signature

10 July 2006

Date

STEPHEN VENETIANER

Printed or Typed Name

610-270-5040

Telephone Number

Vice President, Pharmaceuticals

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.